These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 7703829)

  • 21. Utilization of recombinant human GM-CSF to enhance peripheral progenitor cell yield for autologous transplantation.
    Ho AD; Haas R; Korbling M; Dietz M; Hunstein W
    Bone Marrow Transplant; 1991; 7 Suppl 1():13-7. PubMed ID: 1675138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum in bone marrow transplanted patients.
    Sallerfors B; Olofsson T; Lenhoff S
    Bone Marrow Transplant; 1991 Sep; 8(3):191-5. PubMed ID: 1720339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
    Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP
    Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
    Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
    Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation.
    Pene R; Appelbaum FR; Fisher L; Lilleby K; Nemunaitis J; Storb R; Buckner CD
    Bone Marrow Transplant; 1993 Mar; 11(3):219-22. PubMed ID: 8467286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. G-CSF after autologous bone marrow transplantation for malignant diseases in children. Spanish Working Party for Bone Marrow Transplantation in Children.
    Madero L; Muõnz A; Diaz de Heredia A; Martínez A; Badell I; Esquembre C; Ramírez M; Otheo E; Olive A; Sastre A
    Bone Marrow Transplant; 1995 Mar; 15(3):349-51. PubMed ID: 7541268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. G-CSF is a major component of colony-stimulating activity (CSA) in the plasma of patients with multiple myeloma after treatment with high-dose melphalan (HDM).
    Joffe JK; Bell JB; Denham S; Adshead F; Millar JL; Millar BC
    Exp Hematol; 1995 Apr; 23(4):376-82. PubMed ID: 7534716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of recombinant GM-CSF following allogeneic BMTs for aplastic anemia.
    Chap L; Schiller G; Nimer SD
    Bone Marrow Transplant; 1993 Aug; 12(2):173-5. PubMed ID: 8401368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autologous blood progenitor cell transplantation in relapsed Hodgkin's disease--the role of haematopoietic growth factors.
    Haas R; Hohaus S; Ehrhardt R; Goldschmidt H; Hunstein W
    Bone Marrow Transplant; 1993; 11 Suppl 2():30-5. PubMed ID: 8101459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.
    Spitzer G; Adkins D; Mathews M; Velasquez W; Bowers C; Dunphy F; Kronmueller N; Niemeyer R; McIntyre W; Petruska P
    Bone Marrow Transplant; 1997 Dec; 20(11):921-30. PubMed ID: 9422470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation.
    Cetkovský P; Koza V; Jindra P; Skopek P; Svojgrová M
    Bone Marrow Transplant; 1997 Oct; 20(8):639-41. PubMed ID: 9383226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
    Elkordy M; Crump M; Vredenburgh JJ; Petros WP; Hussein A; Rubin P; Ross M; Gilbert C; Modlin C; Meisenberg B; Coniglio D; Rabinowitz J; Laughlin M; Kurtzberg J; Peters WP
    Bone Marrow Transplant; 1997 Feb; 19(4):315-22. PubMed ID: 9051240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis.
    Peters BG; Adkins DR; Harrison BR; Velasquez WS; Dunphy FR; Petruska PJ; Bowers CE; Niemeyer R; McIntyre W; Vrahnos D; Auberry SE; Spitzer G
    Bone Marrow Transplant; 1996 Jul; 18(1):93-102. PubMed ID: 8832001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukaemia: double-blind placebo controlled trial.
    Powles R; Treleaven J; Millar J; Gordon-Smith EC; Tiley C; Findlay M; Teo C; Duncombe A; Robinson G
    Bone Marrow Transplant; 1991; 7 Suppl 2():85-6. PubMed ID: 1878735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation.
    Ippoliti C; Przepiorka D; Giralt S; Andersson BS; Wallerstein RO; Gutterman J; Deisseroth AB; Champlin RE
    Bone Marrow Transplant; 1993 Jan; 11(1):55-9. PubMed ID: 8094309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant human granulocyte-macrophage colony stimulating factor (rh GM-CSF) after bone marrow transplantation.
    Link H; Freund M; Kirchner H; Stoll M; Schmid H; Bucsky P; Seidel J; Schulz G; Schmidt RE; Riehm H
    Behring Inst Mitt; 1988 Aug; (83):313-9. PubMed ID: 3071346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.
    Ozcan M; Ustün C; Akçağlayan E; Akan H; Arslan O; Ilhan O; Beksaç M; Gürman G; Demirer T; Arat M; Celebi H; Konuk N; Uysal A; Koç H
    Bone Marrow Transplant; 2001 Mar; 27(5):499-505. PubMed ID: 11313683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. IL-3 BMT Study Team.
    Schulman KA; Dorsainvil D; Yabroff KR; DiCesare J; Felser J; Eisenberg JM; Glick HA
    Bone Marrow Transplant; 1998 Mar; 21(6):607-14. PubMed ID: 9543065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
    Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
    J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.